Xeplocop-M Tablet is a combination medication containing Levocetirizine 5mg and Montelukast 10mg, indicated for the management of allergic conditions such as allergic rhinitis and chronic urticaria. Levocetirizine, a third-generation non-sedating antihistamine, selectively inhibits peripheral H1 receptors, thereby reducing symptoms like sneezing, rhinorrhea, nasal itching, and urticaria-associated pruritus. Montelukast, a leukotriene receptor antagonist, blocks cysteinyl leukotriene receptors (CysLT1), mitigating bronchoconstriction, inflammation, and mucus production commonly seen in allergic airway diseases. The synergistic action of these agents provides comprehensive relief from allergic symptoms by targeting multiple inflammatory pathways. Xeplocop-M is typically administered orally once daily, with or without food, as prescribed by a healthcare professional. It is well-tolerated, with a low incidence of adverse effects; however, some patients may experience headache, fatigue, or gastrointestinal discomfort. Caution is advised in patients with hepatic impairment or a history of neuropsychiatric events. This combination therapy offers an effective and convenient option for patients requiring simultaneous control of histamine- and leukotriene-mediated allergic manifestations, improving quality of life and symptom management. Always consult a healthcare provider before initiating treatment with Xeplocop-M Tablet.